Table 1.
Clinical data of patients included in the study.
| Variable | ||
|---|---|---|
| Total patients | 51 | |
| Male gender, n (%) | 19 (37%) | |
| Diagnosis at blood sample | ||
| ET | 14 (28%) | |
| PV | 16 (31%) | |
| PreMF | 7 (14%) | |
| PMF | 14 (28%) | |
| Driver mutation | ||
| JAK2V617F | 24 (47%) | |
| CALR | 23 (45%) | |
| Triple negative | 3 (6%) | |
| MPL | 1 (2%) | |
| Treatment at time of blood sampling | ||
| Interferon-alpha | 16 (31%) | |
| Hydroxyurea | 15 (29%) | |
| None | 9 (18%) | |
| Anagrelide | 5 (10%) | |
| Anagrelide and hydroxyurea | 4 (8%) | |
| Phlebotomy | 2 (4%) | |
| Rituximab | 1 (2) | |
| DIPSS score | ||
| Low-risk | 6 (43%) | |
| Intermediate-1 risk | 7 (50%) | |
| Intermediate-2 risk | 1 (7%) | |
| High-risk | 0 (0%) | |
| Transformation/progression, yes | 9 (18%) | |
| Secondary malignancy, yes | 11 (22%) | |
| Complete hematological response | 36 (71%) | |
| Age in years at diagnosis, median (min - max) | 55.9 (17–84) | |
| Age in years at draw of study sample, median (min - max) | 66.9 (25 – 84) | |
| DFR-defined response | 36 (71%) | |
| DFRx2 defined response | 19 (37%) |